Study guide

12.2 Phenotypic Detection of Resistance

ASCP Microbiology Technologist M ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current M(ASCP) Exam Facts 1.2 CAT, Scoring, Retakes, and CMP 1.3 Eligibility Routes and Clinical Experience

2 Preanalytic: Collection and Transport

2.1 Patient Identification and Specimen Labeling 2.2 Specimen Collection, Sterile Technique, and Blood Cultures 2.3 Transport Devices, Atmosphere, Time, and Temperature

3 Preanalytic: Processing, Media, and Incubation

3.1 Prioritization, Rejection, and Specimen Preparation 3.2 Media Types, Components, and Selection 3.3 Inoculation, Incubation Conditions, and Slide Preparation

4 Preanalytic: Stains

4.1 Gram Stain: Procedure, Principle, and Interpretation 4.2 Acid-Fast and Modified Acid-Fast Stains 4.3 KOH, Calcofluor-White, Trichrome, Giemsa, and Acridine Orange

5 Bacteriology: Blood and Bone Marrow

5.1 Blood Culture Systems and Rapid Identification 5.2 Bloodstream Pathogens and Skin Flora Significance 5.3 Endocarditis, Bone Marrow Pathogens, and Pathogenicity

6 Bacteriology: CSF and Sterile Body Fluids

6.1 CSF Sources and Acute Meningitis Pathogens 6.2 Shunt Infections, CSF Correlates, Antigen and Molecular Methods 6.3 Sterile Body Fluids: Pathogens, Flora, and Molecular Methods

7 Bacteriology: Respiratory Tract

7.1 Lower Respiratory Specimens, CAP, and HAP Pathogens 7.2 Cystic Fibrosis Pathogens and Quantitative Reporting 7.3 Upper Respiratory: Pharyngitis, Otitis, Sinusitis, Antigen/Molecular

8 Bacteriology: Gastrointestinal Tract

8.1 Enteric Pathogens: Culture and Colony Morphology 8.2 Clostridioides difficile, Shiga Toxin, and Serotyping 8.3 Helicobacter pylori Detection and GI Pathogenicity

9 Bacteriology: Skin, Soft Tissue, and Bone

9.1 Skin, Soft Tissue, and Bone Pathogens 9.2 Bite Wounds and Zoonotic Infections 9.3 SST Pathogenicity and Virulence Mechanisms

10 Bacteriology: Genital Tract and Urine

10.1 Genital Flora and Vaginitis Pathogens 10.2 Neisseria gonorrhoeae, Chlamydia trachomatis, GBS, and Mycoplasma 10.3 Urinary Pathogens, Colony Counts, and Urinalysis Correlation

11 Bacteriology: Identification Methods

11.1 Colony Morphology and Rapid Presumptive Tests 11.2 Conventional Biochemicals and Commercial Kits 11.3 Automated Methods, MALDI-TOF MS, Molecular, and 16S Sequencing

12 Bacteriology: Antimicrobial Susceptibility and Resistance

12.1 Microbroth Dilution, Disk Diffusion, and Gradient Diffusion 12.2 Phenotypic Detection of Resistance 12.3 Antibiotic Classes, Intrinsic Resistance, and Genetic Markers

13 Bacteriology: Resistance Screening and Select Agents

13.1 MRSA/MSSA, VRE, ESBL/CRE Screening 13.2 BSL-3 Pathogens and Select-Agent Presumptive Identification 13.3 Laboratory Response Network and Select-Agent Pathogenicity

14 Mycobacteriology and Nocardia

14.1 Specimens, Major Pathogens, and Disease States 14.2 Acid-Fast Reaction, Colony Morphology, and Growth Characteristics 14.3 Identification Methods, Direct Molecular Detection, and TB Therapy

15 Virology

15.1 Respiratory, Vesicle, Meningitis, and GI Viruses 15.2 Hepatitis, HIV, and Immunocompromised-Host Viruses 15.3 Direct Detection Methods and HPV Cervical Screening

16 Parasitology

16.1 Blood, Tissue, and Brain Protozoa 16.2 Intestinal/Urogenital Protozoa and Helminths 16.3 Microscopy, Antigen/Molecular Detection, Insects and Arthropods

17 Mycology

17.1 Yeasts: Candida, Cryptococcus, and Malassezia 17.2 Dimorphic Fungi and Dermatophytes 17.3 Mucorales, Hyaline Molds, Pneumocystis, and Identification Methods

18 Serology

18.1 Immunoglobulin Response and Antigen-Antibody Methods 18.2 Viral Serodiagnosis: Hepatitis, EBV, HIV, CMV, Rubella, Measles 18.3 Treponema, Borrelia, and TB Infection Serodiagnosis

19 Laboratory Operations: Postanalytic Procedures and Quality

19.1 Documentation, Critical Values, Corrected Reports, and Public Health 19.2 Quality Control, Root-Cause Analysis, and POCT 19.3 Proficiency Testing, Competency, and Accreditation

20 Laboratory Operations: Safety, Mathematics, and Instrumentation

20.1 Biosafety, PPE, Bloodborne Pathogens, and SDS 20.2 Emergencies and Packaging/Transportation of Specimens 20.3 Laboratory Mathematics and Instrumentation

12.2 Phenotypic Detection of Resistance

Key Takeaways Explain This Topic AI

Nitrocefin turns yellow to red when a classic beta-lactamase hydrolyzes the ring; it is high-yield for Haemophilus, Moraxella, and penicillinase gonococci, but it does not replace ESBL or carbapenemase methods.

Historical ESBL confirmation with clavulanate forced penicillins, cephalosporins, and aztreonam to resistant; current lowered cephalosporin breakpoints support reporting those drugs as tested (carbapenem-sparing).

A D-shaped flattening of the clindamycin zone next to erythromycin is inducible clindamycin resistance; do not report clindamycin susceptible if the D-test is positive.

mCIM detects carbapenem inactivation; eCIM recovery with EDTA points to a metallo-enzyme, while mCIM-positive/eCIM-negative fits a serine carbapenemase such as KPC. Carba NP is a rapid hydrolysis color test.

MRSA is predicted by a cefoxitin screen (mecA/PBP2a). VRE is an acquired vancomycin phenotype, usually vanA/vanB in E. faecium or E. faecalis, distinct from intrinsic vanC in motile pigmented enterococci.

Last updated: August 2026

Phenotypic resistance tests answer a different question from a routine MIC: is a mechanism present that would make a susceptible-looking result unsafe? Official outline II.K expects nitrocefin beta-lactamase, ESBL screening/confirmation in historical versus current interpretive context, the D-test for inducible clindamycin resistance, carbapenemase methods (mCIM/eCIM and Carba NP as concepts), the MRSA cefoxitin screen, and VRE detection. Do not convert these items into SM-only cascade reporting of which drugs to list by body site.

Nitrocefin (Cefinase) beta-lactamase

Nitrocefin is a chromogenic cephalosporin. Intact reagent is yellow ; hydrolysis of the beta-lactam ring turns it red . Rub a colony onto a moistened disk or use a drop of reagent and read color within the insert window (often up to 5–15 minutes). A positive test means the isolate produces an enzyme that opens a beta-lactam ring — most classically TEM-type penicillinases.

High-yield uses:

Haemophilus influenzae / H. parainfluenzae : nitrocefin-positive isolates are ampicillin-resistant penicillinase producers. Nitrocefin-negative ampicillin-resistant Haemophilus implies a non-enzyme mechanism (PBP changes, BLNAR) that HTM disk or MIC must catch.

Moraxella catarrhalis : nearly all isolates are nitrocefin-positive, which is why ampicillin fails.

Neisseria gonorrhoeae : penicillinase-producing N. gonorrhoeae (PPNG).

Selected anaerobes and staphylococci: penicillinase that predicts penicillin failure.

Nitrocefin is not a universal resistance oracle. Extended-spectrum beta-lactamases and carbapenemases may hydrolyze nitrocefin poorly or slowly. A yellow disk does not prove the isolate lacks ESBL or KPC. Do not use nitrocefin in place of a cefoxitin MRSA screen or in place of a carbapenemase method.

ESBL: historical clavulanate confirmation versus current carbapenem-sparing interpretation

Extended-spectrum beta-lactamases (TEM, SHV, CTX-M families) hydrolyze penicillins and expanded-spectrum cephalosporins and are inhibited by clavulanate . They do not, by themselves, efficiently hydrolyze carbapenems.

Historical CLSI approach:

Screen Enterobacterales with cefotaxime, ceftriaxone, ceftazidime, or aztreonam using former (higher) breakpoints that could still call some ESBL producers “susceptible.”

Confirm with clavulanate combination tests: cefotaxime ± clavulanate and ceftazidime ± clavulanate as disks (a large zone increase, traditionally taught as ≥5 mm) or MIC wells (a ≥3 two-fold dilution / 8-fold MIC decrease with clavulanate). Those increments are confirmatory method criteria, not a year-stamped M100 therapy table.

If ESBL was confirmed, laboratories edited the report: penicillins, cephalosporins, and aztreonam were reported resistant even when an individual agent tested susceptible in vitro, because of documented clinical failures. That edit pushed therapy toward carbapenems.

Current CLSI interpretive philosophy (after cephalosporin and aztreonam breakpoints were lowered): report each of those drugs as tested against the current M100 MIC or zone. Routine ESBL confirmation is no longer required to rewrite every cephalosporin result for therapy. Lower breakpoints are designed so that isolates with clinically important ESBL-level hydrolysis test intermediate or resistant to the drugs that would fail. That is the carbapenem-sparing interpretation : a cefepime result that is truly susceptible at the current breakpoint may be reported as such rather than automatically forcing every beta-lactam except carbapenems to R. ESBL phenotypic or molecular detection remains valuable for infection control and epidemiology; it is no longer the mandatory editor of every cephalosporin. Know both eras — stems still ask what clavulanate confirmation used to do to the report — but apply reporting-as-tested logic unless the question is clearly historical.

AmpC ( Enterobacter , Klebsiella aerogenes , Citrobacter freundii , Serratia ) is not an ESBL. AmpC is poorly inhibited by clavulanate and can look like a failed ESBL confirmatory test. Cefoxitin resistance plus no clavulanate restoration of cefotaxime points to AmpC, not CTX-M.

D-test: inducible clindamycin resistance

Macrolide-lincosamide-streptogramin B (MLS_B) resistance is often encoded by erm , which methylates 23S rRNA. Expression may be constitutive (erythromycin R and clindamycin R) or inducible (erythromycin R, clindamycin S in vitro until a macrolide inducer is present). Clindamycin is a weak inducer in the well but can fail in vivo if erm is inducible.

For staphylococci (and beta-hemolytic streptococci when tables require it) that test erythromycin-resistant and clindamycin-susceptible or intermediate , place an erythromycin disk and a clindamycin disk at CLSI spacing so the zones can interact. After overnight incubation, inspect the clindamycin zone on the side facing erythromycin. Flattening into a D shape is a positive D-test (inducible clindamycin resistance, iMLS_B). Report clindamycin resistant. Do not report clindamycin susceptible if the D-test is positive.

A negative D-test with erythromycin R / clindamycin S is typical of efflux ( msrA in staphylococci): clindamycin remains active and may be reported susceptible. Disks placed too far apart miss the D; disks stacked on top of each other are unreadable technique, not a new phenotype.

Phenotypic pattern Mechanism Reporting consequence

Nitrocefin yellow → red Classic penicillinase (TEM-type) Ampicillin/penicillin fail ( Haemophilus , Moraxella , PPNG)

Clavulanate restores cefotaxime/ceftazidime ESBL (TEM/SHV/CTX-M) Historical: edit cephalosporins/aztreonam to R; current: report as tested

  • D-shaped clindamycin flattening Inducible erm (iMLS_B) Report clindamycin R; do not report S
  • Erythromycin R, clindamycin S, no D Efflux ( msrA ) Clindamycin may remain S
  • mCIM-positive, eCIM zone recovered Metallo-carbapenemase (NDM/VIM/IMP) Carbapenemase present; zinc-dependent
  • mCIM-positive, eCIM still inactivated Serine carbapenemase (KPC) Carbapenemase present; not EDTA-inhibited
  • Cefoxitin screen resistant mecA /PBP2a Report oxacillin-R MRSA
  • Vancomycin screen growth, E. faecium Acquired vanA / vanB VRE; distinguish from intrinsic vanC
  • Carbapenemases: mCIM, eCIM, and Carba NP

Carbapenemase-producing Enterobacterales, and some Pseudomonas / Acinetobacter , need a mechanism test because meropenem MICs can sit near breakpoints.

Modified carbapenem inactivation method (mCIM): incubate a heavy suspension of the test organism with a meropenem disk, then place that disk onto a lawn of E. coli ATCC 25922. If the test organism destroyed meropenem, the indicator E. coli grows up to the disk (small or no zone) = mCIM positive . If meropenem survives, a large zone remains = mCIM negative .

EDTA-modified CIM (eCIM): run in parallel with EDTA, which chelates zinc. Metallo-beta-lactamases (NDM, VIM, IMP) need zinc; EDTA suppresses them, so the eCIM disk recovers a larger zone than mCIM. Serine carbapenemases (KPC, some OXA) are not zinc enzymes; eCIM stays inactivated like mCIM. Teach the pattern: mCIM-positive / eCIM-positive → MBL ; mCIM-positive / eCIM-negative → serine enzyme such as KPC . Do not treat a single millimeter cutoff as a frozen M100 therapy table — the concept is EDTA rescue versus no rescue.

Carba NP is a rapid colorimetric hydrolysis assay: imipenem in a pH-indicator mix turns yellow when a carbapenemase dumps acid. It is a phenotypic screen, not a gene name. Some OXA enzymes give false negatives; a negative Carba NP does not bless a high meropenem MIC.

MRSA cefoxitin screen and VRE

MRSA is mecA (rarely mecC ) encoding PBP2a , a transpeptidase with low beta-lactam affinity. Cefoxitin is the phenotypic surrogate because it induces mecA better than oxacillin. A cefoxitin disk or cefoxitin MIC that interprets as resistant is reported as oxacillin-resistant S. aureus . PBP2a latex or mecA PCR can confirm. Borderline oxacillin-resistant S. aureus (BORSA) without mecA is not MRSA.

VRE usually means acquired vanA or vanB in E. faecium or E. faecalis . Vancomycin agar screen (commonly 6 µg/mL BHI) or vancomycin MIC/disk per CLSI, incubated a full 24 hours , detects resistant enterococci. vanA typically confers high-level vancomycin and teicoplanin resistance (D-Ala-D-Lac). vanB is vancomycin-resistant, teicoplanin-susceptible. Motile pigmented species ( E. casseliflavus , E. gallinarum ) carry intrinsic vanC and low-level vancomycin resistance — they are not the outbreak vanA E. faecium clone. Identify to species before labeling an isolate “VRE” for infection control.

Work ASCP M practice questions on D-shaped clindamycin zones, clavulanate confirmation stems, cefoxitin MRSA screens, and mCIM/eCIM patterns.

Loading diagram... Phenotypic mechanism pathway: nitrocefin, ESBL eras, D-test, carbapenemases, MRSA, VRE

Typical time-to-result scale — nitrocefin is minutes; VRE screens need a full 24-hour read